BioNTX’s board of directors has appointed Gina Ford, DPh., MBA, as the organization’s chief executive officer.
As CEO, Ford will lead BioNTX’s strategic vision and operational priorities, drive disciplined growth, and ensure it provides meaningful, measurable value to its members, the nonprofit said. She will concentrate on boosting industry alignment, increasing the region’s national visibility, and charting a clear roadmap to “speed innovation, attract investment, and improve long-term competitiveness in the life sciences sector across North Texas.”
“It’s a privilege to step into the role of CEO and to work with the exceptional leaders, innovators, and partners who make North Texas a dynamic hub for bioscience,” Ford said in a statement. “BioNTX has built a powerful platform for connection and advancement, and I’m committed to amplifying that impact as we enter this next stage of growth.”
“I look forward to deepening strategic partnerships, broadening opportunities for innovation, and supporting the breakthroughs that will shape the region’s future,” Ford added
Advancing biotech and improving patient outcomes
Ford was chosen after a six-month review of multiple candidates led by “a skilled executive recruiter” and a committee of the BioNTX board, BioNTX said.
“The search process was rigorous and comprehensive, ensuring we selected a leader with the vision and experience to guide BioNTX forward,” said Kathleen Otto Rosenblum, former CEO of BioNTX. “Gina distinguished herself with her strong, future focused approach to advancing bioscience and healthcare innovation in North Texas. I’m confident that under her leadership, BioNTX is well-positioned for the future.”
An accomplished leader with more than two decades of leadership experience across the life sciences, biotechnology, and pharmaceutical sectors, Ford has led organizations in corporate strategy, commercialization and globalization planning, and patient advocacy. She comes to BioNTX from Women In Bio, Inc., where she served as CEO and led exceptional growth in fundraising, engagement across national and local networks, and advanced programs supporting women in life science careers.
As a Doctor of Pharmacy with an MBA, Ford offers extensive experience spanning the bioscience life cycle, from startup and capital formation through commercialization and growth. Her long-standing commitment to improving patient outcomes is in excellent alignment with BioNTX’s mission to “advance innovation that improves lives by putting the patient first,” the organization said.
Leadership transition
Kathleen Otto-Rosenblum, former CEO of BioNTX [Photo: BioNTX]
Ford’s appointment follows Otto’s retirement from BioNTX after a stellar career, most recently dedicated to advancing biotech innovation in North Texas. To support the leadership transition, Otto will stay involved and serve as an advisor to support Ford and BioNTX.
“Gina brings an exceptional depth of industry experience and an inspiring track record of growth, partnership-building, and strategic vision,” said Jason Weitjes, BioNTX board chair. “We’re confident that Gina’s strategic acumen, industry relationships, and operational experience will build on BioNTX’s strong foundation and support continued growth across our region. We are grateful for Kathleen’s service and pleased that she will remain engaged with BioNTX as an advisor and member of our board.”
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.
R E A D N E X T
-
The Pittsburgh-headquartered nonprofit's executive director, Dallas-based Gina Ford, takes up the newly created top post of the organization, which empowers women across biotech, pharma, and life sciences to lead, engage, and grow at every career stage.
-
Eido Bio’s three co-founders are taking on menopause, research gaps, and a market where women’s health “sort of starts and stops with birth control.” The biotech startup is raising a Series A to launch clinical trials for a menopause treatment—and help shift the science toward women.
-
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
-
One of TIME Magazine's Best Inventions of 2024, Light Bio's glow-in-the-dark Firefly Petunia goes on sale this Friday at Calloway's Nursery locations across DFW. Gardeners can get insights about the flower at special after-hours events that same day.
-
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
